31
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      De Novo Donor‐Specific HLA Antibody Formation in Two Patients With Crigler‐Najjar Syndrome Type I Following Human Hepatocyte Transplantation With Partial Hepatectomy Preconditioning

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Clinical hepatocyte transplantation is hampered by low engraftment rates and gradual loss of function resulting in incomplete correction of the underlying disease. Preconditioning with partial hepatectomy improves engraftment in animal studies. Our aim was to study safety and efficacy of partial hepatectomy preconditioning in clinical hepatocyte transplantation. Two patients with Crigler‐Najjar syndrome type I underwent liver resection followed by hepatocyte transplantation. A transient increase of hepatocyte growth factor was seen, suggesting that this procedure provides a regenerative stimulus. Serum bilirubin was decreased by 50%, and presence of bilirubin glucuronides in bile confirmed graft function in both cases; however, graft function was lost due to discontinuation of immunosuppressive therapy in one patient. In the other patient, serum bilirubin gradually increased to pretransplant concentrations after ≈600 days. In both cases, loss of graft function was temporally associated with emergence of human leukocyte antigen donor‐specific antibodies (DSAs). In conclusion, partial hepatectomy in combination with hepatocyte transplantation was safe and induced a robust release of hepatocyte growth factor, but its efficacy on hepatocyte engraftment needs to be evaluated with additional studies. To our knowledge, this study provides the first description of de novo DSAs after hepatocyte transplantation associated with graft loss.

          Abstract

          The authors report two cases of hepatocyte transplantation with partial hepatectomy preconditioning in patients with Crigler‐Najjar syndrome type I, in which after initial successful allograft function, donor hepatocytes are lost in association with emergence of donor‐specific human leukocyte antigen antibodies.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: not found
          • Article: not found

          Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London.

            On September 6 and 7, 2009 a meeting was held in London to identify and discuss what are perceived to be current roadblocks to effective hepatocyte transplantation as it is currently practiced in the clinics and, where possible, to offer suggestions to overcome the blocks and improve the outcomes for this cellular therapy. Present were representatives of most of the active clinical hepatocyte transplant programs along with other scientists who have contributed substantial basic research to this field. Over the 2-day sessions based on the experience of the participants, numerous roadblocks or challenges were identified, including the source of cells for the transplants and problems with tracking cells following transplantation. Much of the discussion was focused on methods to improve engraftment and proliferation of donor cells posttransplantation. The group concluded that, for now, parenchymal hepatocytes isolated from donor livers remain the best cell source for transplantation. It was reported that investigations with other cell sources, including stem cells, were at the preclinical and early clinical stages. Numerous methods to modulate the immune reaction and vascular changes that accompany hepatocyte transplantation were proposed. It was agreed that, to obtain sufficient levels of repopulation of liver with donor cells in patients with metabolic liver disease, some form of liver preconditioning would likely be required to enhance the engraftment and/or proliferation of donor cells. It was reported that clinical protocols for preconditioning by hepatic irradiation, portal vein embolization, and surgical resection had been developed and that clinical studies using these protocols would be initiated in the near future. Participants concluded that sharing information between the groups, including standard information concerning the quality and function of the transplanted cells prior to transplantation, clinical information on outcomes, and standard preconditioning protocols, would help move the field forward and was encouraged.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation.

              This study defined negative outcomes of solid organ transplantation, proposed a new classification of complications by severity, and applied the classification to evaluate the results of orthotopic liver transplantation (OLT). The lack of uniform reporting of negative outcomes has made reports of transplantation procedures difficult to interpret and compare. In fact, only mortality is well reported; morbidity rates and severity of complications have been poorly described. Based on previous definition and classification of complications for general surgery, a new classification for transplantation in four grades is proposed. Results including risk factors of the first 215 OLTs performed at the University of Toronto have been evaluated using the classification. All but two patients (99%) had at least one complication of any kind, 92% of patients surviving more than 3 months had grade 1 (minor) complications, 74% had grade 2 (life-threatening) complications, and 30% had grade 3 (residual disability or cancer) complications. Twenty-nine per cent of patients had grade 4 complications (retransplantation or death). The most common grade 1 complications were steroid responsive rejection (69% of patients) and infection that did not require antibiotics or invasive procedures (23%). Grade 2 complications primarily were infection requiring antibiotics or invasive procedures (64%), postoperative bleeding requiring > 3 units of packed red cells (35%), primary dysfunction (26%), and biliary disease treated with antibiotics or requiring invasive procedures (18%). The most frequent grade 3 complication was renal failure, which is defined as a permanent rise in serum creatinine levels > or = twice the pretransplantation values (11%). Grade 4 complications (retransplantation or death) mainly were infection (14%) and primary dysfunction (11%). Comparison between the first and last 50 OLTs of the series indicates a significant decrease in the mean number of grade 1 and 2 complications. This was partially a result of better medical status of patients at the time of transplantation. Using univariate and multivariate analyses of risk factors, the best predictor of grade 1 complications was donor obesity; for grade 2 complications, the best predictor was a donor liver rewarming time of > 90 minutes, and for grade 3 and 4 complications, the best predictor was the APACHE II scoring system and donor cardiac arrest. Standardized definitions and classifications of complications of transplantation will allow us to better evaluate and compare results of transplantation among centers and over time, and better compare effectiveness of new therapies. Orthotopic liver transplantation still is a procedure with high morbidity that requires careful analysis of risk factors to optimize selection of patients and organ sharing.
                Bookmark

                Author and article information

                Contributors
                carl.jorns@ki.se
                Journal
                Am J Transplant
                Am. J. Transplant
                10.1111/(ISSN)1600-6143
                AJT
                American Journal of Transplantation
                John Wiley and Sons Inc. (Hoboken )
                1600-6135
                1600-6143
                02 November 2015
                March 2016
                : 16
                : 3 ( doiID: 10.1111/ajt.2016.16.issue-3 )
                : 1021-1030
                Affiliations
                [ 1 ] Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Transplantation Surgery, Karolinska Institute Karolinska University Hospital Huddinge StockholmSweden
                [ 2 ] Division of Pediatrics, Karolinska InstituteKarolinska University Hospital Huddinge StockholmSweden
                [ 3 ] Department of Laboratory Medicine, Division of Pathology, Karolinska InstituteKarolinska University Hospital Huddinge StockholmSweden
                [ 4 ] Division of Clinical Immunology and Transfusion, Karolinska InstituteKarolinska University Hospital Huddinge StockholmSweden
                [ 5 ] Tytgat Institute for Liver and Intestinal ResearchAcademic Medical Center AmsterdamThe Netherlands
                [ 6 ] Department of PediatricsAalborg University Hospital AalborgDenmark
                Author notes
                [*] [* ] Corresponding author: Carl Jorns, carl.jorns@ 123456ki.se

                [†]

                Contributed equally.

                Article
                AJT13487
                10.1111/ajt.13487
                5061095
                26523372
                f6edd0fa-23ae-40f2-a4c1-8207b102a129
                © 2015 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 07 January 2015
                : 05 August 2015
                : 06 August 2015
                Page count
                Figures: 5, Tables: 4, Pages: 10, Words: 6182
                Funding
                Funded by: Research Strategy Committee Karolinska Institute
                Funded by: Stockholm County Council
                Funded by: Swedish Research Council (VR)
                Categories
                Case Report
                Case Report
                Custom metadata
                2.0
                ajt13487
                March 2016
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:12.10.2016

                Transplantation
                translational research/science,cellular transplantation (non‐islet),liver transplantation/hepatology,regenerative medicine,liver (native) function/dysfunction,liver disease: congenital,immune regulation

                Comments

                Comment on this article